Full course of PD-1/PD-L1 blockades — Competitive Intelligence Brief

Full course of PD-1/PD-L1 blockades (Full course of PD-1/PD-L1 blockades) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: PD-1/PD-L1 inhibitor. Area: Oncology.

phase 3 PD-1/PD-L1 inhibitor PD-1 and PD-L1 Oncology Small molecule

Target snapshot

Full course of PD-1/PD-L1 blockades (Full course of PD-1/PD-L1 blockades) — Sun Yat-sen University. PD-1/PD-L1 blockade releases the brakes on the immune system by inhibiting checkpoint proteins that cancer cells use to evade T-cell attack, thereby restoring anti-tumor immunity.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Full course of PD-1/PD-L1 blockades TARGET	Full course of PD-1/PD-L1 blockades	Sun Yat-sen University	phase 3	PD-1/PD-L1 inhibitor	PD-1 and PD-L1
PD-1 / PD-L1 monoclonal antibody	PD-1 / PD-L1 monoclonal antibody	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	marketed	PD-1/PD-L1 inhibitor	PD-1 and/or PD-L1
Combination PD-1/PD-L1 ICI + VEGFR-TKI	Combination PD-1/PD-L1 ICI + VEGFR-TKI	University Hospital, Bordeaux	phase 3	PD-1/PD-L1 inhibitor + VEGFR tyrosine kinase inhibitor combination	PD-1, PD-L1, VEGFR (vascular endothelial growth factor receptor)
PD1/PDL1 inhibitor	PD1/PDL1 inhibitor	Second Affiliated Hospital of Guangzhou Medical University	phase 3	PD-1/PD-L1 inhibitor	PD-1 and/or PD-L1
TQB2303	TQB2303	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	phase 3	PD-1/PD-L1 inhibitor	PD-1/PD-L1
SSGJ-707	SSGJ-707	Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.	phase 3	PD-1/PD-L1 inhibitor	PD-1
HL140 5/10	HL140 5/10	Hanlim Pharm. Co., Ltd.	phase 3	PD-1/PD-L1 inhibitor	PD-1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (PD-1/PD-L1 inhibitor class)

1. Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · 3 drugs in this class
2. AstraZeneca · 2 drugs in this class
3. Cancer Institute and Hospital, Chinese Academy of Medical Sciences · 1 drug in this class
4. Hanlim Pharm. Co., Ltd. · 1 drug in this class
5. EMD Serono · 1 drug in this class
6. EMS · 1 drug in this class
7. Fujian Cancer Hospital · 1 drug in this class
8. Elixiron Immunotherapeutics (Hong Kong) Ltd. · 1 drug in this class
9. Cellvax Therapeutics Inc · 1 drug in this class
10. Anhui Shi, MD · 1 drug in this class